(NOVC.DE) Stock Fundamental Analysis
FRA:NOVC - Deutsche Boerse Ag - DK0060534915 - Common Stock - Currency: EUR
NOVC gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 52 industry peers in the Pharmaceuticals industry. NOVC scores excellent points on both the profitability and health parts. This is a solid base for a good stock. NOVC is not overvalued while it is showing excellent growth. This is an interesting combination. These ratings could make NOVC a good candidate for growth and quality investing.
1. Profitability
1.1 Basic Checks
In the past year NOVC was profitable.
NOVC had a positive operating cash flow in the past year.
Each year in the past 5 years NOVC has been profitable.
Each year in the past 5 years NOVC had a positive operating cash flow.
1.2 Ratios
The Return On Assets of NOVC (23.95%) is better than 95.56% of its industry peers.
NOVC has a Return On Equity of 74.32%. This is amongst the best in the industry. NOVC outperforms 95.56% of its industry peers.
The Return On Invested Capital of NOVC (55.96%) is better than 97.78% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for NOVC is significantly above the industry average of 12.96%.
The 3 year average ROIC (49.65%) for NOVC is below the current ROIC(55.96%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 23.95% | ||
| ROE | 74.32% | ||
| ROIC | 55.96% |
ROA(3y)25.55%
ROA(5y)28.51%
ROE(3y)66.85%
ROE(5y)68.54%
ROIC(3y)49.65%
ROIC(5y)55.99%
1.3 Margins
The Profit Margin of NOVC (33.40%) is better than 91.11% of its industry peers.
In the last couple of years the Profit Margin of NOVC has declined.
Looking at the Operating Margin, with a value of 42.80%, NOVC belongs to the top of the industry, outperforming 95.56% of the companies in the same industry.
In the last couple of years the Operating Margin of NOVC has remained more or less at the same level.
NOVC has a better Gross Margin (84.35%) than 84.44% of its industry peers.
In the last couple of years the Gross Margin of NOVC has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 42.8% | ||
| PM (TTM) | 33.4% | ||
| GM | 84.35% |
OM growth 3Y-0.97%
OM growth 5Y-0.64%
PM growth 3Y-0.57%
PM growth 5Y-1.67%
GM growth 3Y-0.02%
GM growth 5Y-0.07%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so NOVC is creating value.
Compared to 1 year ago, NOVC has less shares outstanding
Compared to 1 year ago, NOVC has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 11.18 indicates that NOVC is not in any danger for bankruptcy at the moment.
NOVC's Altman-Z score of 11.18 is amongst the best of the industry. NOVC outperforms 93.33% of its industry peers.
NOVC has a debt to FCF ratio of 0.38. This is a very positive value and a sign of high solvency as it would only need 0.38 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 0.38, NOVC belongs to the top of the industry, outperforming 91.11% of the companies in the same industry.
A Debt/Equity ratio of 0.21 indicates that NOVC is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.21, NOVC is in line with its industry, outperforming 60.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.21 | ||
| Debt/FCF | 0.38 | ||
| Altman-Z | 11.18 |
ROIC/WACC7.69
WACC7.28%
2.3 Liquidity
NOVC has a Current Ratio of 0.88. This is a bad value and indicates that NOVC is not financially healthy enough and could expect problems in meeting its short term obligations.
NOVC's Current ratio of 0.88 is on the low side compared to the rest of the industry. NOVC is outperformed by 84.44% of its industry peers.
A Quick Ratio of 0.70 indicates that NOVC may have some problems paying its short term obligations.
NOVC's Quick ratio of 0.70 is on the low side compared to the rest of the industry. NOVC is outperformed by 82.22% of its industry peers.
NOVC does not score too well on the current and quick ratio evaluation. However, as it has excellent solvency and profitability, these ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.88 | ||
| Quick Ratio | 0.7 |
3. Growth
3.1 Past
NOVC shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -32.68%.
Measured over the past 5 years, NOVC shows a small growth in Earnings Per Share. The EPS has been growing by 3.48% on average per year.
The Revenue has grown by 28.03% in the past year. This is a very strong growth!
Measured over the past years, NOVC shows a quite strong growth in Revenue. The Revenue has been growing by 9.64% on average per year.
EPS 1Y (TTM)-32.68%
EPS 3Y3.69%
EPS 5Y3.48%
EPS Q2Q%-26.37%
Revenue 1Y (TTM)28.03%
Revenue growth 3Y13.19%
Revenue growth 5Y9.64%
Sales Q2Q%31.59%
3.2 Future
NOVC is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.79% yearly.
Based on estimates for the next years, NOVC will show a quite strong growth in Revenue. The Revenue will grow by 13.65% on average per year.
EPS Next Y96.77%
EPS Next 2Y52.67%
EPS Next 3Y40.31%
EPS Next 5Y25.79%
Revenue Next Year27.56%
Revenue Next 2Y22.92%
Revenue Next 3Y20.4%
Revenue Next 5Y13.65%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
NOVC is valuated quite expensively with a Price/Earnings ratio of 43.17.
Based on the Price/Earnings ratio, NOVC is valued a bit more expensive than 64.44% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 29.62, NOVC is valued a bit more expensive.
The Price/Forward Earnings ratio is 15.13, which indicates a correct valuation of NOVC.
Based on the Price/Forward Earnings ratio, NOVC is valued a bit cheaper than 64.44% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.70. NOVC is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 43.17 | ||
| Fwd PE | 15.13 |
4.2 Price Multiples
64.44% of the companies in the same industry are cheaper than NOVC, based on the Enterprise Value to EBITDA ratio.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of NOVC is on the same level as its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 42.68 | ||
| EV/EBITDA | 30.33 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of NOVC may justify a higher PE ratio.
NOVC's earnings are expected to grow with 40.31% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.45
PEG (5Y)12.41
EPS Next 2Y52.67%
EPS Next 3Y40.31%
5. Dividend
5.1 Amount
NOVC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap386.28B
Analysts70.63
Price Target169.94 (96.83%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP41.57%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.26%
Min EPS beat(2)-6.63%
Max EPS beat(2)2.11%
EPS beat(4)3
Avg EPS beat(4)-0.09%
Min EPS beat(4)-6.63%
Max EPS beat(4)2.85%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)99180.3%
Min Revenue beat(2)97265.9%
Max Revenue beat(2)101095%
Revenue beat(4)4
Avg Revenue beat(4)100079%
Min Revenue beat(4)97265.9%
Max Revenue beat(4)101151%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.68%
PT rev (3m)6.75%
EPS NQ rev (1m)-50.34%
EPS NQ rev (3m)-49.42%
EPS NY rev (1m)0.22%
EPS NY rev (3m)4.6%
Revenue NQ rev (1m)-99.9%
Revenue NQ rev (3m)-99.9%
Revenue NY rev (1m)0.24%
Revenue NY rev (3m)3.71%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 43.17 | ||
| Fwd PE | 15.13 | ||
| P/S | 14.31 | ||
| P/FCF | 42.68 | ||
| P/OCF | 32.1 | ||
| P/B | 31.84 | ||
| P/tB | 72.51 | ||
| EV/EBITDA | 30.33 |
EPS(TTM)2
EY2.32%
EPS(NY)5.71
Fwd EY6.61%
FCF(TTM)2.02
FCFY2.34%
OCF(TTM)2.69
OCFY3.12%
SpS6.03
BVpS2.71
TBVpS1.19
PEG (NY)0.45
PEG (5Y)12.41
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 23.95% | ||
| ROE | 74.32% | ||
| ROCE | 69.41% | ||
| ROIC | 55.96% | ||
| ROICexc | 79.18% | ||
| ROICexgc | 187.85% | ||
| OM | 42.8% | ||
| PM (TTM) | 33.4% | ||
| GM | 84.35% | ||
| FCFM | 33.53% |
ROA(3y)25.55%
ROA(5y)28.51%
ROE(3y)66.85%
ROE(5y)68.54%
ROIC(3y)49.65%
ROIC(5y)55.99%
ROICexc(3y)59.43%
ROICexc(5y)70.56%
ROICexgc(3y)107.14%
ROICexgc(5y)103.87%
ROCE(3y)66.16%
ROCE(5y)72.5%
ROICexcg growth 3Y12.28%
ROICexcg growth 5Y2.92%
ROICexc growth 3Y-8.96%
ROICexc growth 5Y-9.74%
OM growth 3Y-0.97%
OM growth 5Y-0.64%
PM growth 3Y-0.57%
PM growth 5Y-1.67%
GM growth 3Y-0.02%
GM growth 5Y-0.07%
F-Score7
Asset Turnover0.72
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.21 | ||
| Debt/FCF | 0.38 | ||
| Debt/EBITDA | 0.21 | ||
| Cap/Depr | 278.9% | ||
| Cap/Sales | 11.04% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | 100.38% | ||
| Current Ratio | 0.88 | ||
| Quick Ratio | 0.7 | ||
| Altman-Z | 11.18 |
F-Score7
WACC7.28%
ROIC/WACC7.69
Cap/Depr(3y)235.6%
Cap/Depr(5y)244.27%
Cap/Sales(3y)10.33%
Cap/Sales(5y)10.26%
Profit Quality(3y)95.36%
Profit Quality(5y)92.36%
High Growth Momentum
Growth
EPS 1Y (TTM)-32.68%
EPS 3Y3.69%
EPS 5Y3.48%
EPS Q2Q%-26.37%
EPS Next Y96.77%
EPS Next 2Y52.67%
EPS Next 3Y40.31%
EPS Next 5Y25.79%
Revenue 1Y (TTM)28.03%
Revenue growth 3Y13.19%
Revenue growth 5Y9.64%
Sales Q2Q%31.59%
Revenue Next Year27.56%
Revenue Next 2Y22.92%
Revenue Next 3Y20.4%
Revenue Next 5Y13.65%
EBIT growth 1Y29.73%
EBIT growth 3Y12.1%
EBIT growth 5Y8.94%
EBIT Next Year38.11%
EBIT Next 3Y23.19%
EBIT Next 5Y17.5%
FCF growth 1Y112.16%
FCF growth 3Y21.73%
FCF growth 5Y14.55%
OCF growth 1Y65.59%
OCF growth 3Y19.03%
OCF growth 5Y13.89%